We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

68 hedge funds and large institutions have $612M invested in ArriVent BioPharma in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,167% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 3

700% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 2

51% more capital invested

Capital invested by funds: $404M → $612M (+$208M)

26% more funds holding

Funds holding: 54 → 68 (+14)

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

12.48% more ownership

Funds ownership: 64.66% → 77.13% (+12%)

Holders
68
Holders Change
+14
Holders Change %
+25.93%
% of All Funds
0.98%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
16
Increased
38
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$28.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$15.8M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$8.22M
4
State Street
State Street
Massachusetts
+$7.34M
5
Millennium Management
Millennium Management
New York
+$4.64M

Top Sellers

Rank Fund Capital Flow
1
AA
AlphaCentric Advisors
Puerto Rico
-$1.61M
2
HLAM
Hidden Lake Asset Management
New York
-$689K
3
Walleye Capital
Walleye Capital
New York
-$464K
4
Jane Street
Jane Street
New York
-$107K
5
TRCT
Tower Research Capital (TRC)
New York
-$29.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
51
Royal Bank of Canada
Ontario, Canada
$81K +$57.6K +2,539 +274%
AIP
52
Ameritas Investment Partners
Nebraska
$67.1K +$42.5K +1,873 +191%
Legal & General Group
53
Legal & General Group
United Kingdom
$66.8K +$42.9K +1,890 +198%
California State Teachers Retirement System (CalSTRS)
54
California State Teachers Retirement System (CalSTRS)
California
$48.5K +$30.7K +1,353 +190%
SO
55
STRS Ohio
Ohio
$40K – – –
RIM
56
Rakuten Investment Management
Japan
$33.9K – – –
AB
57
Amalgamated Bank
New York
$23K +$9.6K +423 +78%
AWM
58
Avior Wealth Management
Nebraska
$20.9K +$11.3K +498 +128%
TRCT
59
Tower Research Capital (TRC)
New York
$4.3K -$29.7K -1,309 -88%
AAP
60
Arax Advisory Partners
Colorado
$2.8K – – –
Carson Wealth (CWM LLC)
61
Carson Wealth (CWM LLC)
Nebraska
$2K +$817 +36 +62%
CPA
62
Capital Performance Advisors
California
$1.57K +$1.52K +67 New
SCM
63
Sterling Capital Management
North Carolina
$1.39K +$1.34K +59 New
ACM
64
Aster Capital Management
United Arab Emirates
$1.03K +$999 +44 New
BTI
65
Blue Trust Inc
Georgia
$723 +$885 +39 New
Nisa Investment Advisors
66
Nisa Investment Advisors
Missouri
$635 – – –
GI
67
GAMMA Investing
California
$588 +$340 +15 +150%
RIL
68
Rothschild Investment LLC
Illinois
$235 +$113 +5 +100%
HLAM
69
Hidden Lake Asset Management
New York
– -$689K -37,121 Closed
Walleye Capital
70
Walleye Capital
New York
– -$464K -25,000 Closed
1 2
3

AVBP Hedge Fund Activity: Q3 2024 in Review

68 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q3 2024, worth a combined $612M — up 51% from $404M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new AVBP positions and 2 closed out — a net gain of 14 holders — while 38 added to existing stakes and 3 trimmed.

The largest buyer was BlackRock, adding an estimated $28.8M. The largest seller was AlphaCentric Advisors, cutting an estimated $1.61M.

  • 68 institutional investors held ArriVent BioPharma (AVBP) as of Q3 2024, up from 54 in Q2 2024.
  • Funds reported $612M of ArriVent BioPharma stock for Q3 2024, up 51% quarter-over-quarter.
  • 16 funds opened new ArriVent BioPharma positions in Q3 2024 and 2 closed out, a net change of +14 holders.
  • The largest ArriVent BioPharma buyer in Q3 2024 was BlackRock, an estimated $28.8M added.
  • The largest ArriVent BioPharma seller in Q3 2024 was AlphaCentric Advisors, an estimated $1.61M sold.

Based on aggregated 13F filings for Q3 2024.